Direkt zum Inhalt
Merck
  • A plasma cell variant of Castleman's disease treated successfully with cimetidine. Case report and review of the literature.

A plasma cell variant of Castleman's disease treated successfully with cimetidine. Case report and review of the literature.

Anticancer research (1996-01-01)
V Barbounis, A Efremidis
ZUSAMMENFASSUNG

Castleman's disease is a rare benign condition of uncertain etiology, with several forms. It is postulated that a dysregulated inflammatory response may play a role in the pathogenesis of this disease. We report on a case of Castleman's disease treated with the histamine receptor-2 antagonist cimetidine with favourable response, suggesting that cimetidine may be helpful in the treatment of this disease.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Cimetidin
Supelco
Cimetidin, Pharmaceutical Secondary Standard; Certified Reference Material
Cimetidin, European Pharmacopoeia (EP) Reference Standard
Cimetidin für die Systemeignung, European Pharmacopoeia (EP) Reference Standard
Cimetidin für die Peakidentifizierung, European Pharmacopoeia (EP) Reference Standard